{"anticipatedPostingDate":"2010-06","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Incidence of donor products that met release criteria in accordance with FDA regulations (Lot Release Criteria for allogeneic, interleukin-2 (IL-2) activated natural killer (NK) cell products (BB-IND 8847) and the NK cell numbers infused (donor NK cell dose 1.5-8.0 x 10\\^7/kg).","groups":[{"description":"Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.","id":"OG000","title":"Patients Treated With Natural Killer Cells"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Day 0","title":"Number of Patients With Adequate Natural Killer Cells Infused","type":"SECONDARY","unitOfMeasure":"Participants"}